AI platform developed by NUS researchers finds best combination of available therapies against COVID-19

Researchers from the National University of Singapore have utilised a ground-breaking AI platform to find an optimal combination of available therapies against COVID-19. The research team identified the drug combination from over 530,000 possibilities within two weeks, cutting down the number of tests typically needed by hundreds of thousands.

Read more

Remdesivir for COVID-19: FDA Approved but Still Unproven

In a review of evidence from the most reliable data from randomized trials to find likely small-to-moderate effects of remdesivir, researchers say that totality of evidence compiled before the WHO trial results justifies compassionate use of remdesivir for severely ill patients. A smaller trial in China showed significantly decreased mean recovery time but no suggestion of a mortality benefit. ACTT-1 found the same mean recovery time and a suggestion of a mortality benefit that did not achieve statistical significance.

Read more

New Research Supports Sofosbuvir in Combination with Other Antivirals for COVID-19

Columbia Engineering researchers report that Sofosbuvir-terminated RNA is more resistant to the proofreader of SARS-CoV-2, the virus that causes COVID-19, than Remdesivir-terminated RNA. The results of the new study, published today by the Nature Research journal Scientific Reports, support the use of the FDA-approved hepatitis C drug EPCLUSA—Sofosbuvir/Velpatasvir—in combination with other drugs in COVID-19 clinical trials.

Read more

First Patients in NIH ACTIV-3 Clinical Trial Enroll in Dallas

On Wednesday in Dallas, just one day after the initiative was launched by the National Institutes of Health (NIH), Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.

Read more

Baylor Scott & White Research Institute Expands Efforts in the Fight Against COVID-19

As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.

Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.

Read more

Montefiore and Einstein Test a New Drug Combination to Conquer COVID-19

Montefiore Health System and Albert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people hospitalized with severe COVID-19 infection. The new iteration of the trial, known as ACTT 2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Read more